Arrowhead Pharma Inc
COM · CUSIP 042797209
1
institutional holders
+0 vs Q1 2026
29
shares reported held*
$2.3kreported value*
1 new
0 added
0 reduced
1 sold out
net sold ≈ $8.4m (-104.9k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $80.52.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2025 | 1 |
| Q2 2025 | 1 |
| Q3 2025 | 1 |
| Q4 2025 | 1 |
| Q1 2026 | 1 |
| Q2 2026 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q2 2025 | 0 | 0 |
| Q3 2025 | 0 | 1 |
| Q4 2025 | 1 | 0 |
| Q1 2026 | 0 | 1 |
| Q2 2026 | 1 | 1 |
Biggest buyers
| MANNING & NAPIER ADVISORS LLC | New | +29 |
Biggest sellers
| EVERETT HARRIS & CO /CA/ | Sold out | -104.9k |
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| MANNING & NAPIER ADVISORS LLC 0.00% of their portfolio | 29 $2.3k | New |